Illumina, Inc. $ILMN Position Cut by Cannell & Spears LLC

Cannell & Spears LLC lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.7% in the 3rd quarter, Holdings Channel reports. The fund owned 239,301 shares of the life sciences company’s stock after selling 9,119 shares during the period. Cannell & Spears LLC’s holdings in Illumina were worth $22,726,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of ILMN. Quent Capital LLC bought a new stake in Illumina in the 3rd quarter valued at about $29,000. Aster Capital Management DIFC Ltd acquired a new position in Illumina during the 3rd quarter valued at about $33,000. Mather Group LLC. bought a new position in Illumina in the 3rd quarter worth about $46,000. Evelyn Partners Investment Management LLP grew its position in Illumina by 4,927.3% in the 2nd quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock worth $49,000 after purchasing an additional 542 shares during the last quarter. Finally, SJS Investment Consulting Inc. increased its stake in shares of Illumina by 13,225.0% in the third quarter. SJS Investment Consulting Inc. now owns 533 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 529 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ILMN shares. JPMorgan Chase & Co. cut their price target on Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Stifel Nicolaus raised their target price on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research note on Wednesday, January 7th. Robert W. Baird set a $137.00 price target on Illumina in a research note on Friday, February 6th. Finally, Piper Sandler lowered their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Six research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and an average target price of $129.69.

Insider Activity

In other news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares in the company, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 2.60% of the company’s stock.

Illumina Trading Up 2.9%

Illumina stock opened at $118.94 on Friday. The firm has a 50 day simple moving average of $133.15 and a 200-day simple moving average of $119.96. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. The stock has a market capitalization of $18.19 billion, a PE ratio of 21.82, a price-to-earnings-growth ratio of 2.28 and a beta of 1.45. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $155.53.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the business earned $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.